Intrauterine devices (IUDs), or stérilets as they are called in France, are “an excellent method of contraception,” says Isabelle Yoldjian, medical director at the Agence nationale de sécurité du médicament et des produits de santé (ANSM, France’s National Agency for the Safety of Medicines and Health Products). However, not all IUDs offer the same benefit-risk balance. According to a French study, published November 25, 2025H, in the New England Journal of Medicine Evidence, women using the lowest-dose hormonal IUD, Jaydess (Bayer), have a two-to-four times higher risk of ectopic pregnancy compared to women who chose other IUDs.
“That risk still remains much lower than the risk of ectopic pregnancy among women using no contraception at all,” noted epidemiologist Mahmoud Zureik, who coordinated the study as director of EPI-PHARE, a group responsible for pharmaco-epidemiology studies in France using health insurance reimbursement data.
In France, Bayer stopped marketing this device on November 27, 2024. However, “it is possible that some [Jaydess] IUDs may still be available in community pharmacies until February 2027,” warned the ANSM. In total, between 55,000 and 60,000 women in France currently have a Jaydess IUD.
You have 73.01% of this article left to read. The rest is for subscribers only.
